PD-L1 Expression and Outcome in Patients with Metastatic Non-Small Cell Lung Cancer and EGFR Mutations Receiving EGFR-TKI as Frontline Treatment.
Cheng-Yu ChangYi-Chun LaiYu-Feng WeiChung-Yu ChenShih-Chieh ChangPublished in: OncoTargets and therapy (2021)
For patients with metastatic NSCLC and EGFR mutations, PD-L1 expression is not uncommon, but no significant influence on clinical outcomes was observed in patients receiving standard initial treatment.